Data Bytes: BMS’s takeout of MyoKardia marks most expensive CV acquisition to date

At $13.1 billion, Bristol Myers’ acquisition of MyoKardia tops the list of most expensive cardiovascular-focused acquisitions since BioCentury’s BCIQ database began tracking these transactions in 2009. 

Bristol Myers Squibb Co. (NYSE:BMY) paid $225 per share, a 61% premium to its Friday close of $139.60, for the cardiovascular pipeline from MyoKardia Inc. (NASDAQ:MYOK). The main draw was mavacamten, a cardiac myosin inhibitor in Phase III testing for obstructive hypertrophic cardiomyopathy. An NDA submission is planned for 1Q21. ...